109 related articles for article (PubMed ID: 23085878)
1. Models of excellence: improving oncology drug development.
Sharma MR; Maitland ML; Ratain MJ
Clin Pharmacol Ther; 2012 Nov; 92(5):548-50. PubMed ID: 23085878
[TBL] [Abstract][Full Text] [Related]
2. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.
Claret L; Lu JF; Bruno R; Hsu CP; Hei YJ; Sun YN
Clin Pharmacol Ther; 2012 Nov; 92(5):631-4. PubMed ID: 22910440
[TBL] [Abstract][Full Text] [Related]
3. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
[TBL] [Abstract][Full Text] [Related]
5. Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592).
Hillner BE
J Natl Cancer Inst Monogr; 1995; (19):65-7. PubMed ID: 7577209
[No Abstract] [Full Text] [Related]
6. Neo-adjuvant chemotherapy in non-small cell lung cancer (NSCLC).
Santo A; Genestreti G; Sava T; Manno P; Terzi A; Molino AM; Cetto GL
Ann Oncol; 2006 May; 17 Suppl 5():v55-61. PubMed ID: 16807464
[No Abstract] [Full Text] [Related]
7. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Lee JJ; Han JY; Lee DH; Kim HY; Chun JH; Lee HG; Yoon SM; Lee SY; Lee JS
Jpn J Clin Oncol; 2006 Dec; 36(12):761-7. PubMed ID: 17043059
[TBL] [Abstract][Full Text] [Related]
9. Why do oncologists prescribe--or not prescribe--conventional chemotherapy to geriatric patients with metastatic non-small cell lung cancer?
Jatoi A; Hillman S; Stella P; Rowland K; Morton R; Dakhil S
J Support Oncol; 2006; 4(7):311-2. PubMed ID: 16892691
[No Abstract] [Full Text] [Related]
10. Referral to medical oncologists: are there barriers at the gate?
Neugut AI; Grann VR
J Clin Oncol; 2002 Apr; 20(7):1716-8. PubMed ID: 11919225
[No Abstract] [Full Text] [Related]
11. How do U.S. medical oncologists learn and apply new clinical trials information from press releases in nonmedical media? A case study based on ECOG 4599.
Dornbusch D; Allegra C; Willey J; Andrews M; Leff R; Epstein J; Jones J; Lokey L; Green MR
Oncologist; 2006 Jan; 11(1):31-8. PubMed ID: 16401711
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology--42nd annual meeting. Current approaches to lung cancer therapy. 2-6 June 2006, Atlanta, GA, USA.
Chan D; Cleverley J
IDrugs; 2006 Aug; 9(8):523-5. PubMed ID: 16871454
[No Abstract] [Full Text] [Related]
13. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Veyrat-Follet C; Bruno R; Olivares R; Rhodes GR; Chaikin P
Clin Pharmacol Ther; 2000 Dec; 68(6):677-87. PubMed ID: 11180028
[TBL] [Abstract][Full Text] [Related]
14. First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience.
Sandler A
Semin Oncol; 1999 Oct; 26(5 Suppl 15):44-51. PubMed ID: 10566611
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
16. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
Bradley JD; Bae K; Graham MV; Byhardt R; Govindan R; Fowler J; Purdy JA; Michalski JM; Gore E; Choy H
J Clin Oncol; 2010 May; 28(14):2475-80. PubMed ID: 20368547
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Albain KS; Swann RS; Rusch VW; Turrisi AT; Shepherd FA; Smith C; Chen Y; Livingston RB; Feins RH; Gandara DR; Fry WA; Darling G; Johnson DH; Green MR; Miller RC; Ley J; Sause WT; Cox JD
Lancet; 2009 Aug; 374(9687):379-86. PubMed ID: 19632716
[TBL] [Abstract][Full Text] [Related]
18. Afatinib and chemotherapy in non-small-cell lung cancer.
Brower V
Lancet Oncol; 2016 Feb; 17(2):e47. PubMed ID: 26710711
[No Abstract] [Full Text] [Related]
19. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.
Pfister DG; Johnson DH; Azzoli CG; Sause W; Smith TJ; Baker S; Olak J; Stover D; Strawn JR; Turrisi AT; Somerfield MR;
J Clin Oncol; 2004 Jan; 22(2):330-53. PubMed ID: 14691125
[No Abstract] [Full Text] [Related]
20. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
